Indian Snakeroot
OTHER NAME(S): Ajmaline, Alseroxylon, Arbre aux Serpents, Arbre de Serpents, Bois de Couleuvre, Chandra, Chandrika, Chota-Chand, Covanamilpori, Dhan-barua, Dhanburua, Dhanmarna, Java Devil-Pepper, Pagla-Ka-Dawa, Patalagandhi, Preparation 1043, Racine de Couleuvre, Racine de Serpent, Raudixin, Rauwolfae Radix, Rauwolfia, Rauwolfia Serpentina, Rauwolfiawurzel, Sarpgandha, Sarpagandha, Serpentaire de l'Inde, Serpentine, Serpentine-Wood, Serpina, Serpiria, She Gen Mu, Snake Root, Snakewood, Rauvolfia serpentina, Raíz de serpiente india, Rauvolfia serpentina
Overview
Indian snakeroot (Rauvolfia serpentina) is an evergreen shrub found in Southeast Asia. The root is used as medicine. It's considered an endangered species.
Indian snakeroot contains small amounts of chemicals such as reserpine and yohimbine, which are prescription drugs that can cause serious side effects.
People use Indian snakeroot for high blood pressure, anxiety, constipation, malaria, insomnia, and many other conditions, but there is no good scientific evidence to support these uses.
Don't confuse Indian snakeroot with Rauvolfia vomitoria or Yohimbe. These are not the same.
Uses
We currently have no information for Indian Snakeroot overview.
Side Effects
When taken by mouth: Indian snakeroot is possibly unsafe. It contains the drugs reserpine and yohimbine. Most side effects seem to be mild, but high doses might cause low blood pressure and slow heart rate. Long-term use can cause depression.
Precautions
When taken by mouth: Indian snakeroot is possibly unsafe. It contains the drugs reserpine and yohimbine. Most side effects seem to be mild, but high doses might cause low blood pressure and slow heart rate. Long-term use can cause depression.
Pregnancy and breast-feeding: There isn't enough reliable information to know if Indian snakeroot is safe to use when pregnant or breast-feeding. Stay on the safe side and avoid use. The chemicals in Indian snakeroot can be passed to the unborn baby and into breast milk and might cause harm.
Anxiety: Indian snakeroot contains a chemical that might make anxiety worse. Use Indian snakeroot with caution if you have anxiety.
Depression: Indian snakeroot can cause depression, especially in people who have had depression before.
Shock therapy (electroconvulsive therapy, ECT): Indian snakeroot should not be used by people who are receiving ECT. Stop taking Indian snakeroot at least one week before beginning ECT.
Gallbladder disease: Indian snakeroot might make gallbladder disease worse. Use Indian snakeroot with caution if you have gallbladder disease.
Heart disease: Chemicals in Indian snakeroot can increase or decrease blood pressure. Use with caution if you have heart disease or are at risk for heart disease.
Pheochromocytoma: Avoid Indian snakeroot if you have this condition. It might increase the risk of dangerously high blood pressure.
Gastrointestinal (GI) conditions: Indian snakeroot can irritate the stomach and intestines. Don't use it if you have ever had peptic ulcers or other stomach disorders.
Interactions
Moderate Interaction
Be cautious with this combination
- Medications changed by the liver (Cytochrome P450 2D6 (CYP2D6) substrates) interacts with Indian SnakerootSome medications are changed and broken down by the liver. Indian snakeroot might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
- Medications for diabetes (Antidiabetes drugs) interacts with Indian SnakerootIndian snakeroot might lower blood sugar levels. Taking Indian snakeroot along with diabetes medications might cause blood sugar to drop too low. Monitor your blood sugar closely.
- Medications for high blood pressure (Antihypertensive drugs) interacts with Indian SnakerootIndian snakeroot might lower blood pressure. Taking Indian snakeroot along with medications that lower blood pressure might cause blood pressure to go too low. Monitor your blood pressure closely.
- Medications that slow blood clotting (Anticoagulant / Antiplatelet drugs) interacts with Indian SnakerootIndian snakeroot might slow blood clotting. Taking Indian snakeroot along with medications that also slow blood clotting might increase the risk of bruising and bleeding.
- Digoxin (Lanoxin) interacts with Indian SnakerootDigoxin helps the heart beat more strongly. Indian snakeroot seems to slow the heartbeat. Taking Indian snakeroot along with digoxin might decrease the effects of digoxin. Do not take Indian snakeroot if you are taking digoxin.
- Ephedrine interacts with Indian SnakerootEphedrine can speed up the nervous system and make you feel jittery. Indian snakeroot might increase or decrease these effects from ephedrine.
- Levodopa interacts with Indian SnakerootLevodopa is used for Parkinson disease. Taking Indian snakeroot along with levodopa might decrease the effects of levodopa. Do not take Indian snakeroot if you are taking levodopa.
- Medications for depression (MAOIs) interacts with Indian SnakerootIndian snakeroot contains a chemical, called tyrosine, that affects the body. This chemical might increase the side effects of some medications used for depression. Some common MAOIs include phenelzine (Nardil), selegiline (Zelapar), and tranylcypromine (Parnate).
- Medications for mental conditions (Antipsychotic drugs) interacts with Indian SnakerootTaking Indian snakeroot along with some medications for mental conditions might increase the risk of side effects.
- Sedative medications (CNS Depressants) interacts with Indian SnakerootIndian snakeroot might cause sleepiness and slowed breathing. Some medications, called sedatives, can also cause sleepiness and slowed breathing. Taking Indian snakeroot with sedative medications might cause breathing problems and/or too much sleepiness.
- Stimulant drugs interacts with Indian SnakerootStimulants, such as amphetamines and cocaine, speed up the nervous system. By speeding up the nervous system, stimulant medications can increase blood pressure and speed up the heartbeat. Taking Indian snakeroot along with stimulant drugs might cause serious problems including increased heart rate and high blood pressure.
- Medications for depression (Tricyclic Antidepressants) interacts with Indian SnakerootTaking some medications used for depression might alter the effects of Indian snakeroot and increase the risk for side effects.
- Medications for high blood pressure (Beta-blockers) interacts with Indian SnakerootIndian snakeroot might lower blood pressure. Taking Indian snakeroot along with medications that lower blood pressure might cause blood pressure to go too low. Monitor your blood pressure closely.
Dosing
There isn't enough reliable information to know what an appropriate dose of Indian snakeroot might be. Keep in mind that natural products are not always necessarily safe and dosages can be important. Be sure to follow relevant directions on product labels and consult a healthcare professional before using.
References
- Blumenthal M, ed. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. Trans. S. Klein. Boston, MA: American Botanical Council, 1998.
- Leung AY, Foster S. Encyclopedia of Common Natural Ingredients Used in Food, Drugs and Cosmetics. 2nd ed. New York, NY: John Wiley & Sons, 1996.
- McGuffin M, Hobbs C, Upton R, Goldberg A, eds. American Herbal Products Association's Botanical Safety Handbook. Boca Raton, FL: CRC Press, LLC 1997.
- Robbers JE, Speedie MK, Tyler VE. Pharmacognosy and Pharmacobiotechnology. Baltimore, MD: Williams & Wilkins, 1996.
- McEvoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 1998.
- Gruenwald J, Brendler T, Jaenicke C. PDR for Herbal Medicines. 1st ed. Montvale, NJ: Medical Economics Company, Inc., 1998.
- Brinker F. Herb Contraindications and Drug Interactions. 2nd ed. Sandy, OR: Eclectic Medical Publications, 1998.
- Young DS. Effects of Drugs on Clinical Laboratory Tests 4th ed. Washington: AACC Press, 1995.
- Foster S, Tyler VE. Tyler's Honest Herbal, 4th ed., Binghamton, NY: Haworth Herbal Press, 1999.
- Milman N, Scheibel J, Jessen O. Lysine prophylaxis in recurrent herpes simplex labialis: a double-blind, controlled crossover study. Acta Derm Venereol 1980;60:85-7.
- Teloken C, Rhoden EL, Sogari P, et al. Therapeutic effects of high dose yohimbine hydrochloride on organic erectile dysfunction. J Urol 1998;159:122-4.
- Jacobsen FM. Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. J Clin Psychiatry 1992;53:119-22.
- Hollander E, McCarley A. Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers. J Clin Psychiatry 1992;53:207-9.
- Briggs GB, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1998.
- Rani PU, Naidu MU. Subjective and polysomnographic evaluation of a herbal preparation in insomnia. Phytomedicine 1998;5:253-7.
- Sandler B, Aronson P. Yohimbine-induced cutaneous drug eruption, progressive renal failure, and lupus-like syndrome. Urol 1993;41:343-5.
- Kearney T, Tu N, Haller C. Adverse drug events associated with yohimbine-containing products: a retrospective review of the California Poison Control System reported cases. Ann Pharmacother 2010;44:1022-9.
- VandenBrink, B. M., Foti, R. S., Rock, D. A., Wienkers, L. C., and Wahlstrom, J. L. Prediction of CYP2D6 drug interactions from in vitro data: evidence for substrate-dependent inhibition. Drug Metab Dispos. 2012;40(1):47-53.
- Campbell-Tofte, J. I., Molgaard, P., Josefsen, K., Abdallah, Z., Hansen, S. H., Cornett, C., Mu, H., Richter, E. A., Petersen, H. W., Norregaard, J. C., and Winther, K. Randomized and double-blinded pilot clinical study of the safety and anti-diabetic efficacy of the Rauvolfia-Citrus tea, as used in Nigerian traditional medicine. J Ethnopharmacol. 1-27-2011;133(2):402-411.
- Mustonen, P., Savola, J., and Lassila, R. Atipamezole, an imidazoline-type alpha(2)-adrenoceptor inhibitor, binds to human platelets and inhibits their adrenaline-induced aggregation more effectively than yohimbine. Thromb.Res 8-1-2000;99(3):231-237.
- Bagheri, H., Schmitt, L., Berlan, M., and Montastruc, J. L. Effect of 3 weeks treatment with yohimbine on salivary secretion in healthy volunteers and in depressed patients treated with tricyclic antidepressants. Br J Clin Pharmacol 1992;34(6):555-558.
- Albus, M., Zahn, T. P., and Breier, A. Anxiogenic properties of yohimbine. I. Behavioral, physiological and biochemical measures. Eur.Arch.Psychiatry Clin.Neurosci. 1992;241(6):337-344.
- Swann, A. C., Birnbaum, D., Jagar, A. A., Dougherty, D. M., and Moeller, F. G. Acute yohimbine increases laboratory-measured impulsivity in normal subjects. Biol.Psychiatry 5-15-2005;57(10):1209-1211.
- Adeniyi, A. A., Brindley, G. S., Pryor, J. P., and Ralph, D. J. Yohimbine in the treatment of orgasmic dysfunction. Asian J Androl 2007;9(3):403-407.
- Giampreti, A., Lonati, D., Locatelli, C., Rocchi, L., and Campailla, M. T. Acute neurotoxicity after yohimbine ingestion by a body builder. Clin Toxicol.(Phila) 2009;47(8):827-829.
- Myers, A. and Barrueto, F., Jr. Refractory priapism associated with ingestion of yohimbe extract. J Med Toxicol. 2009;5(4):223-225.
- Berlin, I., Crespo-Laumonnier, B., Cournot, A., Landault, C., Aubin, F., Legrand, J. C., and Puech, A. J. The alpha 2-adrenergic receptor antagonist yohimbine inhibits epinephrine-induced platelet aggregation in healthy subjects. Clin Pharmacol.Ther. 1991;49(4):362-369.
- Swann, A. C. Mechanisms of impulsivity in bipolar disorder and related illness. Epidemiol.Psichiatr.Soc. 2010;19(2):120-130.
- Landis, E. and Shore, E. Yohimbine-induced bronchospasm. Chest 1989;96(6):1424.
- Susset, J. G., Tessier, C. D., Wincze, J., Bansal, S., Malhotra, C., and Schwacha, M. G. Effect of yohimbine hydrochloride on erectile impotence: a double-blind study. J Urol. 1989;141(6):1360-1363.
- Braddock, L., Cowen, P. J., Elliott, J. M., Fraser, S., and Stump, K. Binding of yohimbine and imipramine to platelets in depressive illness. Psychol.Med 1986;16(4):765-773.
- Charney, D. S., Heninger, G. R., and Sternberg, D. E. Assessment of alpha 2 adrenergic autoreceptor function in humans: effects of oral yohimbine. Life Sci 6-7-1982;30(23):2033-2041.
- Boon, N. A., Elliott, J. M., Grahame-Smith, D. G., John-Green, T., and Stump, K. A comparison of alpha 2-adrenoreceptor binding characteristics of intact human platelets identified by [3H]-yohimbine and [3H]- dihydroergocryptine. J Auton.Pharmacol 1983;3(2):89-95.
- Siddiqui, M. A., More-O'Ferrall, D., Hammod, R. S., Baime, R. V., and Staddon, A. P. Agranulocytosis associated with yohimbine use. Arch.Intern.Med 6-10-1996;156(11):1235-1237.
- Mann, K., Klingler, T., Noe, S., Roschke, J., Muller, S., and Benkert, O. Effects of yohimbine on sexual experiences and nocturnal penile tumescence and rigidity in erectile dysfunction. Arch.Sex Behav. 1996;25(1):1-16.
- Rowland, D. L., Kallan, K., and Slob, A. K. Yohimbine, erectile capacity, and sexual response in men. Arch Sex Behav 1997;26(1):49-62.
- Riley AJ, Goodman R, Kellett JM, and et al. Double blind trial of yohimbine hydrochloride in the treatment of erection inadequacy. Sexual Marital Ther 1989;4(1):17-26.
- Ruck B, Shih RD, Marcus SM. Hypertensive crisis from herbal treatment of impotence. Am J Emerg Med. 1999;17:317-318.
- Wylie KR. Yohimbine and sinusitis. Br J Psychiatry. 1996;169(3):384-5.
- Lobay D. Rauwolfia in the Treatment of Hypertension. Integr Med (Encinitas). 2015 Jun;14(3):40-6.
- Lowinger P. Rauwolfia serpentina in the control of anxiety. Psychiatr Q. 1957 Jul;31(3):445-53.
- Sheldon MB, Kotte JH. Effect of Rauwolfia serpentina and reserpine on the blood pressure in essential hypertension; a long-term double-blind study. Circulation. 1957 Aug;16(2):200-6.
- Vakil RJ. A clinical trial of Rauwolfia serpentina in essential hypertension. Br Heart J. 1949 Oct;11(4):350-5.
- Azmi MB, Qureshi SA. Methanolic Root Extract of Rauwolfia serpentina Benth Improves the Glycemic, Antiatherogenic, and Cardioprotective Indices in Alloxan-Induced Diabetic Mice. Adv Pharmacol Sci. 2012;2012:376429.
- Dey A, Pandey DK. HPTLC detection of altitudinal variation of the potential antivenin stigmasterol in different populations of the tropical ethnic antidote Rauvolfia serpentina. Asian Pac J Trop Med. 2014 Sep;7S1:S540-5.
- Ezeigbo II, Ezeja MI, Madubuike KG, Ifenkwe DC, Ukweni IA, Udeh NE, Akomas SC. Antidiarrhoeal activity of leaf methanolic extract of Rauwolfia serpentina. Asian Pac J Trop Biomed. 2012 Jun;2(6):430-2. doi: 10.1016/S2221-1691(12)60070-7.
- Pathania S, Randhawa V, Bagler G. Prospecting for novel plant-derived molecules of Rauvolfia serpentina as inhibitors of Aldose Reductase, a potent drug target for diabetes and its complications. PLoS One. 2013 Apr 17;8(4):e61327.
- Azmi MB, Qureshi SA. Rauwolfia serpentina improves altered glucose and lipid homeostasis in fructose-induced type 2 diabetic mice. Pak J Pharm Sci. 2016 Sep;29(5):1619-1624.
- Kumar S, Singh A, Bajpai V, Srivastava M, Singh BP, Ojha S, Kumar B. Simultaneous Determination of Bioactive Monoterpene Indole Alkaloids in Ethanolic Extract of Seven Rauvolfia Species using UHPLC with Hybrid Triple Quadrupole Linear Ion Trap Mass Spectrometry. Phytochem Anal. 2016 Sep;27(5):296-303.
- Eurlings MC, Lens F, Pakusza C, Peelen T, Wieringa JJ, Gravendeel B. Forensic identification of Indian snakeroot (Rauvolfia serpentina Benth. ex Kurz) using DNA barcoding. J Forensic Sci. 2013 May;58(3):822-30.
- Sagi S, Avula B, Wang YH, Khan IA. Quantification and characterization of alkaloids from roots of Rauwolfia serpentina using ultra-high performance liquid chromatography-photo diode array-mass spectrometry. Anal Bioanal Chem. 2016 Jan;408(1):177-90.
- Achor RW, Hanson NO, Gifford RW Jr. Hypertension treated with Rauwolfia serpentina (whole root) and with reserpine; controlled study disclosing occasional severe depression. J Am Med Assoc. 1955 Oct 29;159(9):841-5.
- Wilkins RW, Judson WE. The use of Rauwolfia serpentina in hypertensive patients. N Engl J Med. 1953 Jan 8;248(2):48-53.
- Herman AM, Critchley HD, Duka T. The impact of yohimbine-induced arousal on facets of behavioural impulsivity. Psychopharmacology (Berl). 2019;236(6):1783-1795.
- Metz S, Waiblinger-Grigull T, Schulreich S, et al. Effects of hydrocortisone and yohimbine on decision-making under risk. Psychoneuroendocrinology. 2020;114:104589.
- Ryan JJ, Hanes DA, Corroon J, Taylor J, Bradley R. Prospective safety evaluation of a cardiovascular health dietary supplement in adults with prehypertension and stage I hypertension. J Altern Complement Med 2019;25(2):249-56. doi:10.1089/acm.2018.0311.
- Kuehl LK, Deuter CE, Hellmann-Regen J, Kaczmarczyk M, Otte C, Wingenfeld K. Enhanced noradrenergic activity by yohimbine and differential fear conditioning in patients with major depression with and without adverse childhood experiences. Prog Neuropsychopharmacol Biol Psychiatry. 2020;96:109751.
- Bharucha AE, Skaar T, Andrews CN, et al Relationship of cytochrome P450 pharmacogenetics to the effects of yohimbine on gastrointestinal transit and catecholamines in healthy subjects. Neurogastroenterol Motil. 2008;20(8):891-9.
- Schmauss M, Laakmann G, Dieterle D. Effects of alpha 2-receptor blockade in addition to tricyclic antidepressants in therapy-resistant depression. J Clin Psychopharmacol. 1988;8(2):108-11.
- Wang N, Xie YW, Li MY, et al. Simultaneous determination of five alkaloids from Rauvolfia vomitoria in rat plasma by LC-MS/MS: Application to a comparative pharmacokinetic study in normal and type 2 diabetic rats. J Sep Sci 2021;44(7):1391-1403.
- Azmi MB, Qureshi SA, Haseen Ahmed SD, et al. Therapeutic role of Rauwolfia serpentina in minimizing the risk of glycosylation and associated biomarkers in experimentally induced type 1 diabetic mice. Pak J Pharm Sci 2021;34(1):69-76.